Both sides were right. Both sides missed the structural point.

What the ZOE / ASA Daily30+ ruling actually shows about how supplements get sold.

Epistemic status: this is a post about how supplements get sold, not a claim about any compound's mechanism.

You have probably held a supplement that called itself "natural," or "wholefood," or "just real food," and wondered how much work that word was really doing. For one product, a regulator has now decided it was doing too much. The Advertising Standards Authority upheld its ruling against ZOE's Daily30+ over the line "no ultra-processed pills, no shakes, just real food" last May, and upheld it again on appeal in March. ZOE's co-founder Tim Spector called the decision "a profound failure of logic."

Both are right. Most of the argument since has gone into whether chicory root inulin and nutritional yeast flakes count as "ultra-processed." That is the wrong question. What the case actually shows is the structural pressure on every supplement company that has to compress its evidence onto a label.

The ASA's position holds together on its own terms.

The ruling did not say chicory root inulin is bad for you. It explicitly acknowledged that the ingredients in Daily30+ are nutritionally beneficial, that they make up a small share of the product, and that under the technical Nova classification used by food scientists, Daily30+ is not an ultra-processed food.

What the ASA cared about was a different question. Under CAP Code 3.1, the standard is whether a "significant minority of consumers" could be misled by the wording. The ASA's logic was that people who avoid ultra-processed foods read "wholefood" to mean ingredients close to their natural state, prepared by simple steps. Chicory root inulin is an isolated fibre produced by purification, evaporation, enzymatic treatment, and filtration. A consumer who could not replicate that process in a kitchen would read "no ultra-processed pills, just real food" and assume the supplement contained nothing of that type. The ASA's job is to assess consumer perception, not chemistry.

This is a perfectly coherent regulatory position. It is also a difficult one to satisfy if your product is a supplement.

Spector's defence holds together on its own terms too.

Daily30+ is built on a research-backed thesis: people who eat thirty different plants per week tend to have more diverse gut microbiomes. The product is a fibre concentrate designed to make that target reachable for people who cannot get there from food alone. Chicory root inulin, the ingredient the ASA flagged, is one of the most extensively studied prebiotic fibres in the literature.

When Spector says the ruling lumps health-promoting ingredients in with industrially processed junk food, he is naming a real category error. The Nova classification was built to identify foods whose processing strips nutrition and adds problematic ingredients. Applying that frame to a deliberately concentrated prebiotic fibre flattens a distinction that matters.

Both points are true at once. The ASA is right that "just real food" overshoots what the product is. Spector is right that the chemistry of chicory root inulin is not the chemistry of a frozen ready meal. No SKU-level language can satisfy both simultaneously: whatever label ZOE writes next will either understate the prebiotic fibre case or risk another complaint.

The structural pressure both sides are operating inside.

When a company sells a SKU, every word on the package does two jobs. It has to be evidentially defensible to the regulator and clinically meaningful to the consumer. Those two audiences read the same six words differently. "Wholefood supplement" reads to a regulator as a definable category with a Nova classification underneath. It reads to a consumer as "this is the good kind." The gap between those readings is where the ASA lives.

The deeper problem is that the SKU model forces the company to compress its evidence into the smallest possible space at the moment of purchase. ZOE has hundreds of pages of research behind the "thirty plants a week" thesis. Daily30+ has six words on a Facebook ad. The ASA is not penalising the research; it is penalising the distortion that happens when you compress it into a marketing surface.

The same pattern runs through the supplement category. "Practitioner-grade." "Clinically dosed." "Bioavailable form." Each phrase is technically defensible in context and routinely misleading at the point of purchase, because the context cannot fit on the bottle. The companies that resist this best are the ones whose business model does not require them to compress.

What Distil does differently, and why this isn't a fight we have.

Distil does not sell a SKU. We score 104 compounds against your intake profile and tell you what to take, in what form, at what dose, and what to buy from anyone who sells it well. Chicory root inulin sits in our database as a prebiotic fibre with clinical evidence for short-chain fatty acid production and stool consistency. We do not have to package that into "no ultra-processed pills, just real food." We can use four hundred words instead of six, and the compression problem the ASA was solving for does not arise.

This is why the anti-funnel position is structural, not stylistic. The moment we started selling our own supplements, the same gravitational pull that bent ZOE's Facebook ad would start bending our methodology. Our reports would slowly grow language about which form is "best" rather than which is best-evidenced for which population. Our considered-but-rejected list would shrink, because every rejection is a sale we did not make. (That rejection list, and why we publish it, is the subject of how we grade evidence; the longer version of why the whole company is built this way is in why I built Distil.)

Spector's microbiome research output is separately valuable. ZOE-the-research-programme and ZOE-the-supplement-company share a name but operate under different incentive structures, and the ASA ruling was about the second one.

What to read when a supplement company markets to you.

If you have a ZOE pouch in your kitchen, this is not a post telling you to throw it out. It is a post about how to read the next supplement ad that lands in your feed, including the next one from ZOE.

The structural question to ask before reading any evidence cited in supplement marketing is where the company's compensation comes from. If it is from selling the product being discussed, the evidence in the marketing will reliably be the evidence that supports the product, and language about the product will reliably exceed what the underlying evidence can substantiate. This is not a moral failure on the company's part. It is the gravity of the model.

The supplement companies whose marketing you can most trust are the ones who do not need marketing to sell anything. Cochrane reviews. Examine.com. NHS evidence pages. The boundary between credible and compromised is not at the level of any individual claim. It is at the level of the compensation structure that produces the claim. (If you want to see the version of this applied to specific supplement-drug pairs rather than to marketing, our free interactions checker grades and cites every pair, and what evidence-graded means explains the grading in plain English.)

The closing line.

The ASA was not adjudicating chicory root inulin. It was adjudicating the gap between what evidence can sustain and what a label can sell. That gap exists in every supplement company that has a product to move.

The fight is not avoidable from inside the model. It is only avoidable by sitting outside it.